First Study Evaluating the Safety and Dosage of YG-01 in Patients With Glioblastoma
A legfontosabb adatok
- Ki végzi
- YGION Biomedical GmbH
- Hol
- Vienna (Ausztria)A helyszín megnézése
- Azonosító
- NCT07930338
- EU 2025-524299-44-00
- U1111-1330-5924
- Állapot
- Toborzás még nem indult
- Fázis
- 1. fázis
- Résztvevők
- 15 fő, tervezett
- Kezdés
- 2026. nov.
- Várható befejezés
- 2029. nov.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- YG-01 Dose Level 1
- YG-01 Dose Level 2
- A regiszteradat frissítve
- 2026. november 12.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 35 feltétel megnézéseKevesebb
Egyéb feltételek
- Pre-Production Screening inclusion criteria:
- Patient provided written informed consent for study participation prior to initiation of any study specific activities/procedures
- Histologically confirmed glioblastoma, IDH wild type, WHO CNS Grade 4 - classification according to WHO classification of CNS tumors 2021; patients of dose escalation cohorts are required to have undergone extensive tumor resection documented by post-surgical magnetic resonance imaging (MRI) demonstrating either no contrast enhancement or no greater than 1 cm x 1 cm x 1 cm volume of residual enhancing tumor
- Age ≥18 years
- ECOG 0-1
- At least 4 manufacturable neoepitopes identified in a preceding tumor sample analysis study and availability of a manufacturing slot confirmed by the sponsor
- Stable disease or no measurable disease according to local investigator assessment, following at least two MRI scans taken a minimum of 8 weeks apart, both conducted after the completion of standard 6 weeks radiotherapy with concurrent temozolomide; Pre-Therapy Screening inclusion criteria:
- Having completed maintenance temozolomide therapy, received at least 4 cycles of temozolomide, and having an interval of at least 4 weeks between the last dose of temozolomide and the first administration of study medication
- Stable disease or no measurable disease according to local investigator assessment, following an MRI scan taken after the completion of maintenance temozolomide therapy
- Life expectancy > 3 months at start of study treatment as clinically determined by the investigator
- ECOG 0-1
- Availability of study medication confirmed by the sponsor
- Absolute lymphocyte count (ALC) >0.75 x10\^9/L
- No need for dexamethasone or any other steroid treatment within 1 week prior to baseline
- No need for bevacizumab treatment within 1 week prior to baseline; Pre-Production Screening exclusion criteria:
- Known HIV or active Hepatitis B or C infection, or active infections requiring oral or intravenous antibiotics or known infections that can cause a severe disease and pose a severe danger to lab personnel working on patient's blood or tissue
- Concurrent participation in another interventional clinical trial studying a drug or treatment regimen
- Clinically relevant autoimmune diseases (with the exception of autoimmune thyroid disease) that, in the investigator's judgement, may interfere with study participation
- Immunosuppression, not related to treatment for glioblastoma
- History of severe hypersensitivity reactions
- Any condition that in the judgment of the investigator interferes with the probability that an individual patient may receive and benefit from YG-01 treatment (e.g., high risk of early disease progression / recurrence; immunocompromised status; anticipated compliance issues)
- Clinically relevant illness or condition which may affect the patient's safety during the study or impede the patient's ability to complete the study, as assessed by the investigator
- History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) unless the patient has been disease-free for the last 5 years
- Pregnancy or breastfeeding; Pre-Therapy Screening exclusion criteria:
- Abnormal (≥ grade 2 CTCAE v6.0) laboratory values for hematology, liver and renal function (serum creatinine)
- HIV infection or active Hepatitis B or C infection, or active infections requiring oral or intravenous antibiotics or known infections that can cause a severe disease and pose a severe danger to lab personnel working on patient's blood or tissue
- Concurrent participation in another interventional clinical trial studying a drug or treatment regimen
- Clinically relevant autoimmune diseases (with the exception of autoimmune thyroid disease) that, in the investigator's judgement, may interfere with study participation
- Any vaccination within 2 weeks prior to baseline
- Immunosuppression, not related to prior treatment for glioblastoma
- History of severe hypersensitivity reactions
- Any condition that in the judgment of the investigator interferes with the probability that an individual patient may receive and benefit from YG-01 treatment (e.g., high risk of early disease progression / recurrence; immunocompromised status; anticipated compliance issues)
- Clinically relevant illness or condition which may affect the patient's safety during the study or impede the patient's ability to complete the study, as assessed by the investigator
- History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) unless the patient has been disease-free for the last 5 years
- Pregnancy or breastfeeding
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
A feltételkérdéseket egy MI-rendszer írta a(z) NCT07930338 vizsgálathoz közzétett feltételekből. Szoftver ellenőrizte, nem orvos.
- How old are you?
Ez a vizsgálat jelenleg itt érhető el: Ausztria.
- Medical University of ViennaVienna, AusztriaRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a first-in-human, open-label, single-arm, dose-escalation Phase 1 clinical study evaluating the safety, tolerability, feasibility, and immunogenicity of the YG-01, a personalized neoantigen peptide-based cancer immunotherapy, in patients with diagnosed glioblastoma following standard-of-care therapy. The study will assess the safety and tolerability of repeated administrations of YG-01 and explore immune responses and clinical outcomes following treatment. The study includes sequential dose-escalation cohorts to evaluate the safety and tolerability of increasing dose levels of YG-01 and to identify a recommended dose for further clinical development.
A vizsgálat 2 csoportja
- Dose Level 1A vizsgált kezelés
Patients receive YG-01, a personalized neoantigen immunotherapy comprising patient-specific neoepitope peptides administered subcutaneously at Dose Level 1.
Kezelés: YG-01 Dose Level 1
- Dose Level 2A vizsgált kezelés
Patients receive YG-01 at Dose Level 2 subcutaneously on the same schedule as Dose Level 1, started after Safety Committee review of Dose Level 1.
Kezelés: YG-01 Dose Level 2
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- Phase 1 Dose-escalation Study of YG-01 in Patients With Glioblastoma
- Kérdések a feltételekről
- Forrás: NCT07930338: ki vehet részt
- A regiszteradat frissítve
- 2026. november 12.